Exploring how Guselkumab therapy affects liver and joint health in Psoriatic Arthritis patients with NAFLD

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the shared mechanisms between Nonalcoholic Fatty Liver Disease (NAFLD) and Psoriatic Arthritis (PsA) severity, particularly focusing on the effects of Guselkumab therapy. It involves two visits for PsA patients who also have NAFLD and active disease signs, such as swollen joints or psoriatic plaques. The study aims to assess the impact of biological therapies on liver disorders, joints, and skin by utilizing imaging, metabolomics, and ultrasound-guided synovial biopsies to identify new molecular signatures and therapeutic targets.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adults with diagnosis of PsA fulfilling the classification for PsA (CASPAR) criteria.
2. Must have:

1 or more swollen joint(s) and/or one or more active sites of enthesitis

3\. AND/OR

1 or more psoriatic plaques

4\. No changes in the regular medication regimen within the last three months, and no use of systemic and/or chronic steroids within 8 weeks leading up to the study.

5\. Overweight or obese by BMI ≥ 25.0 kg/m2 or ≥ 23.0 for Asian participants

6\. Patients are starting Guselkumab therapy for PsA as indicated by primary rheumatologist

7\. Elevated liver fat on controlled attenuation parameter (CAP) ≥ 288 dB/m, which is consistent with NAFLD after exclusion of secondary causes of liver disease.

Exclusion Criteria:

1. Patients with prior exposure to IL12/23i, IL-17i, JAKi, or TYK2i. Patients with exposure to more than 2 TNFi.
2. Evidence of other causes of chronic liver disease

   * Hepatitis B as defined as presence of hepatitis B surface antigen (HBsAg).
   * Previous or current infection with Hepatitis C as defined by presence of hepatitis C virus Abin serum (anti-HCV Ab).
   * Autoimmune hepatitis as defined by anti-nuclear antibody (ANA) of 1:160 or greater and liver histology consistent with autoimmune hepatitis or previous response to immunosuppressive therapy.
   * Autoimmune cholestatic liver disorders as defined by elevation of alkaline phosphatase and anti-mitochondrial antibody of greater than 1:80 or liver histology consistent with primary biliary cirrhosis or elevation of alkaline phosphatase and liver histology consistent with sclerosing cholangitis.
   * Wilson disease as defined by ceruloplasmin below the limits of normal and liver histology consistent with Wilson disease.
   * Alpha-1-antitrypsin deficiency as defined by alpha-1-antitrypsin level less than normal and liver histology consistent with alpha-1-antitrypsin deficiency.
   * Hemochromatosis as defined by presence of 3+ or 4+ stainable iron on liver biopsy and homozygosity for C282Y or compound heterozygosity for C282Y/H63D.
   * Drug-induced liver disease as defined on the basis of typical exposure and history.
   * Bile duct obstruction as shown by imaging studies.
   * History of gastrointestinal bypass surgery or ingestion of medications known to produce steatosis, such as corticosteroids, high-dose estrogen, tamoxifen, amiodarone or tetracycline in the previous 6 months.
   * Evidence of cirrhosis or previously known cirrhosis based on the results from previous liver biopsy or history of portal hypertension presented by ascites, hepatic encephalopathy or varices
   * Presence of regular and/or excessive use of alcohol (defined as \>30g/day for males and \>15g/day for females) for a period longer than 2 years at any times in the last 10 years
   * Serum creatinine \> 2.0 mg/dL
   * The subject is a pregnant or nursing female or is planning to become pregnant
   * Life expectancy less than 5 years
3. History of known HIV infection

Where it's running

• University of California, San Diego
  San Diego, California, United States Recruiting

Study contacts

• Study coordinator: Monica Guma
• Email: mguma@health.ucsd.edu
• Phone: 8588226523

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-Term Guselkumab Use in Adults with Inflammatory Bowel Disease

  This study looks at how long adults with Crohn's disease or ulcerative colitis stay on guselkumab in real-world care.

  Recruiting Janssen Research & Development, LLC · Amiens · NCT07822529

• Colonic delivery of two antibodies to see if they reach the bloodstream in healthy people

  This early study tests whether guselkumab and adalimumab given directly into the colon can enter the body in healthy adults.

  Recruiting Phase 1 Surmount Services, Inc. · Maroochydore, Queensland · NCT07788807

• Guselkumab after Ustekinumab in adults with moderate-to-severe psoriasis in routine care

  This study looks at how well guselkumab works for people with moderate-to-severe psoriasis after switching from ustekinumab in everyday clinical practice.

  Recruiting Janssen-Cilag Kft. · Budapest · NCT07746583

• Guselkumab in Moderate-to-Severe Ulcerative Colitis: Real-World Experience

  This real-world study tests whether guselkumab helps adults with moderate-to-severe ulcerative colitis and how safe it is for them.

  Recruiting Second Affiliated Hospital of Wenzhou Medical University · Wenzhou, Zhejiang · NCT07726888

• HLA B Leader in Psoriatic Arthritis

  This study tests whether the HLA B leader gene is more common in people with psoriatic arthritis than in healthy individuals.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens, Picardie · NCT07718815

• TaVNS for Psoriatic Arthritis in Adults

  This study tests whether non-invasive taVNS can help reduce disease activity and improve pain and quality of life in adults with psoriatic arthritis.

  Recruiting Marmara University · Istanbul · NCT07653009

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.